Abstract / Summary
Abstract The rising prevalence of antimicrobial resistance (AMR) has become a major global health concern, therefore, demanding immediate attention. This current study brings forth an unprecedented approach to overcome the antimicrobial resistance of microbes by introducing novel lipopeptide biosurfactant LPA2 and LPA3 locally isolated from Bacillus stercosis NT5 and Bacillus subtilis NT5 respectively. Both LPA2 & LPA3 were tested for antimicrobial activity against AMR Staphylococcus aureus (MTCC3160) and Pseudomonas aeruginosa (MTCC424) through fluorescence-based viability assay and broth dilution assay. On evaluation, LPA2 showed the rfu and OD of 10232 and 0.861 respectively against S. aureus with MIC of 0.647mg/ml after 36 hours of incubation and LPA3 displayed rfu and OD of 5812 and 0.639 against P. aeruginosa respectively, with MIC of 0.323 mg/ml after 36 hours of incubation, which is significantly higher than reported one. Microbial cell examined before and after LP treatment through SEM revealed that LP acts on plasma membrane of AMR bacteria and lyse it which is different from the mode of action of antibiotics in use. Therefore, this difference in mode of action of LP against AMR microbes, supports the high AMA of LPA 2&3, which may be a breakthrough for pharmaceutical industry.